

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March, 2019**

Commission File Number: **001-38480**

**IMV Inc.**

*(Name of registrant)*

**130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IMV Inc.**

Date: March 7, 2019

By: /s/ Pierre Labbé

Name: Pierre Labbé

Title: Chief Financial Officer

---

**Form 6-K Exhibit Index**

<b>Exhibit Number</b>	<b>Document Description</b>
<a href="#">99.1</a>	<a href="#">News Release dated March 7, 2019. IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference</a>

---



**IMV Inc. to Present at the Cowen and Company  
39th Annual Health Care Conference**

**Dartmouth, March 7, 2019** – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that [Pierre Labbé, IMV's Chief Financial Officer](#) will present at the [Cowen and Company 39th Annual Health Care Conference](#), which will be held March 11-13, 2019 in Boston, MA.

IMV's presentation details include:

- **Date:** Wednesday, March 13, 2019
- **Time:** 9:20 – 9:50 a.m. ET
- **Location:** Salon C, 4th Floor at The Marriott Copley Hotel, Boston, MA

There will be a live webcast of IMV's presentation accessible thru the IMV website at: <http://wsw.com/webcast/cowen52/imv/> and the presentation will then be archived for 90 days afterwards. A copy of the presentation will also be available in the Events & Presentations section of IMV's website: [www.imv-inc.com](http://www.imv-inc.com).

**About IMV**

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at [www.imv-inc.com](http://www.imv-inc.com).

###

**Source: IMV Inc.**

**Investor Relations:**

Marc Jasmin, IMV Senior Director, Investor Relations and Communications

O: (902) 492-1819 ext : 1042

M: (514) 617-9481 E: [mjasmin@imv-inc.com](mailto:mjasmin@imv-inc.com)

**Media:**

---

Andrea Cohen, Sam Brown Inc.  
T: (917) 209-7163 E: [andreacohen@sambrown.com](mailto:andreacohen@sambrown.com)

---